DefiniGEN
is an England-based biotechnology company that develops and commercializes human cells and tissue models for the treatment of pancreatic and intestinal diseases... Read moreDefiniGEN
is an England-based biotechnology company that develops and commercializes human cells and tissue models for the treatment of pancreatic and intestinal diseases... Read more
News
Jun 13, 2024
Lab Bulletin
DefiniGEN: DefiniGEN and Atelerix collaborate to ship in vitro cell models internationally without the need for freezing or cryopreservation
Jun 04, 2024
European Biotechnology
DefiniGEN: DefiniGEN and Atelerix prevent freezing damage in cell models
Aug 09, 2021
Cambridge Network
DefiniGEN: DefiniGEN achieves ISO 9001: 2015 certification
Nov 26, 2020
UK Business Angels Association
DefiniGEN: DefiniGEN secures 3.25 million in funding led by BGF
Nov 23, 2020
Angel News
DefiniGEN: BGF invests in human cell products and services provider DefiniGEN
Nov 20, 2020
Cambridge Network
DefiniGEN: DefiniGEN secures 3.25 million in funding to fast-track growth
Nov 19, 2020
privateequitywire
DefiniGEN: BGF backs DefiniGEN in GBP3.25m funding round
Jun 08, 2020
Lab Bulletin
DefiniGEN: DefiniGEN launches tool for coronavirus-specific intestinal cell research
Nov 15, 2018
BioPortfolio
DefiniGEN: DefiniGEN Licenses CRISPRCas9 Gene Editing Technology from Broad Institute to Develop Cell Models for Optimized Metabolic Disease Drug Development
Sep 11, 2018
Cambridge Network
DefiniGEN: DefiniGEN strengthens Board with appointment of Professor Sir John Savill
DefiniGEN Competitors
1
2
3
4
5
6
7
8
9
10